Upsize of Previously Announced Private Placement

December 14, 17

Maricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI)(OTCQB:MRRCF)(FRANKFURT:75M) ("Maricann" or the "Company") is pleased to announce that it has entered into an amended letter of engagement with Eight Capital, under which Eight Capital has now agreed to offer for sale, as sole bookrunner and co-lead agent with Canaccord Genuity Corp., and together with a syndicate of agents including Industrial

Read More

Announces $20 Million Private Placement

December 13, 17

Maricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI)(OTCQB:MRRCF)(FRANKFURT:75M) ("Maricann" or the "Company") is pleased to announce that it has entered into a letter of engagement with Eight Capital, pursuant to which Eight Capital, acting as sole bookrunner and co-lead agent with Canaccord Genuity Corp., has agreed to offer for sale, together with a syndicate of agents (together with Eight

Read More

Signs Definitive Agreement with Lovell Drugs for Medical Cannabis Retail Pharmacy Initiative

December 12, 17

Maricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI)(OTCQB:MRRCF)(FRANKFURT:75M) "Maricann" or the "Company") is pleased to announce that it has entered into a definitive agreement with Lovell Drugs Limited ("Lovell Drugs"), Ontario's oldest pharmacy chain, to be the exclusive provider of medical cannabis to its pharmacies. Lovell Drugs will, in partnership with Maricann, implement a medical cannabis education and access

Read More